The combination of NP@ESCu with anti-PD-L1 therapy provides both a novel therapeutic strategy for colorectal cancer as well as serves as a model for nano-drugs fused with cuproptosis to enhance the efficacy of tumor immunotherapy. This evidence concerns the gene CD274 and neoplasm.